Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -18.12% | -14.33% | -15.64% | 12.45% | 17.54% |
| Total Depreciation and Amortization | -68.73% | -64.21% | -65.93% | -65.08% | -64.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 309.51% | 46.68% | 58.62% | -24.95% | -25.88% |
| Change in Net Operating Assets | 608.94% | 281.45% | 192.43% | 115.35% | 64.18% |
| Cash from Operations | 73.25% | 50.82% | 38.36% | 38.32% | 27.05% |
| Capital Expenditure | -8.49% | -403.39% | -744.00% | -500.00% | -130.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.52% | 8.93% | 7.14% | -13.73% | -18.37% |
| Cash from Investing | 0.00% | -7,766.67% | -224.69% | -211.63% | -72.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -619.18% | -- | -- | -- | -- |
| Issuance of Common Stock | -74.04% | -90.48% | -92.05% | -90.80% | -88.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 90.14% | 49.17% | 78.80% | 78.12% | 75.57% |
| Cash from Financing | -157.84% | -115.45% | -97.21% | -94.06% | -90.23% |
| Foreign Exchange rate Adjustments | -27.43% | 82.85% | 64.05% | -8.18% | -49.34% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.49% | -52.12% | -665.29% | -445.65% | -460.05% |